X
GO

Dr. Michele Carbone's Scientific Publications

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Published in Ca: A Cancer Journal for Clinicians, online version on July 9, 2019

Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high-resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1-associated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested.  The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapties are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.
0 Comments
Mesothelioma: Recent Highlights

Mesothelioma: Recent Highlights

Annals of Translational Medicine 2017: Review Article

Recent discoveries have elucidated some of the mechanisms responsible for the development of mesothelioma. 
0 Comments
FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model

FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model

Journal of Translational Medicine

Abstract Malignant mesothelioma (MM) is a very aggressive type of cancer, with a dismal prognosis and inherent resistance to chemotherapeutics. Development and evaluation of new therapeutic approaches is highly needed. Immunosuppressant FTY720, approved for multiple sclerosis treatment, has recently raised attention for its anti-tumor activity in a variety of cancers. However, its therapeutic potential in MM has not been evaluated yet.
0 Comments
Oncotarget Advance Publication: HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma

Oncotarget Advance Publication: HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma

We studied the effect of ethyl pyruvate (EP), the ethyl ester of pyruvic acid, on the malignant phenotype of MM cells in tissue culture and on tumor growth in vivo using an orthotopic MM xenograft model.
0 Comments
Aspirin may delay growth of asbestos-related cancer

Aspirin may delay growth of asbestos-related cancer

Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression

Aspirin (acetylsalicylic acid, ASA) is the most widely used nonsteriodial anti-inflammatory drug that reduces the incidence, metastatic potential and mortality of many inflammation-induced cancers.  Can it play a role in helping patients with malignant mesothelioma?
0 Comments
RSS